Psoriasis: Geringeres Krebsrisiko unter Interleukin-Inhibitoren

Kridin K, Abdelghaffar M, Mruwat N, Ludwig RJ, Thaçi D. Are interleukin 17 and interleukin 23 inhibitors associated with malignancies? Insights from an international population-based study. J Eur Acad Dermatol Venereol 2023; https://doi.org/10.1111/jdv.19520

[1] Pouplard C et al. Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies. J Eur Acad Dermatol Venereol. 2013 Aug;27 Suppl 3:36-46. doi: 10.1111/jdv.12165. PMID: 23845151.

[2] Trafford AM, et al. Association of Psoriasis With the Risk of Developing or Dying of Cancer: A Systematic Review and Meta-analysis. JAMA Dermatol. 2019 Dec 1;155(12):1390-1403. doi: 10.1001/jamadermatol.2019.3056. PMID: 31617868; PMCID: PMC6802036.